United States
Print page content Print
Increase text size Decrease text size
Text Size
Cytopoint logo

This site is intended for U.S.
animal healthcare professionals

safety information

CYTOPOINT® safety information

CYTOPOINT is a safe choice for virtually every dog with chronic canine atopic dermatitis

  • No known drug interactions—safe in combination with other medications, including1:

    • APOQUEL® (oclacitinib tablet), corticosteroids, cyclosporine and antihistamines
    • Treatments such as parasiticides, antibiotics, antifungals, vaccines, NSAIDs and allergen-specific immunotherapy
  • Targeted mechanism of action may help minimize side effects and avoid unwanted effects on immune function1

  • Does not burden the liver or kidneys

    • CYTOPOINT functions like naturally occurring antibodies and is eliminated via normal protein degradation pathways in the same way, which does not involve the liver or kidneys
  • Safe to use in dogs of any age2

    • Can be used in dogs with concomitant diseases

CYTOPOINT is safe for long-term use

  • Safety in a 7-month laboratory study2

    • CYTOPOINT was shown to be safe when administered to laboratory Beagles at up to 5 times the label dose (10 mg/kg) monthly for 7 months. No treatment effects on clinical observations or clinical pathology were identified
  • Ongoing safety monitoring

    • Ongoing pharmacovigilance monitoring, beginning in July 2015, continues to show a safety profile similar to that seen in clinical trials

Indication: CYTOPOINT aids in the reduction of clinical signs associated with atopic dermatitis in dogs.